KR910011820A - Ltb4 합성 저해제 - Google Patents

Ltb4 합성 저해제 Download PDF

Info

Publication number
KR910011820A
KR910011820A KR1019900020892A KR900020892A KR910011820A KR 910011820 A KR910011820 A KR 910011820A KR 1019900020892 A KR1019900020892 A KR 1019900020892A KR 900020892 A KR900020892 A KR 900020892A KR 910011820 A KR910011820 A KR 910011820A
Authority
KR
South Korea
Prior art keywords
compounds
compound
pharmaceutically acceptable
alkyl
carbon atoms
Prior art date
Application number
KR1019900020892A
Other languages
English (en)
Inventor
웨이크필드 쥬릭 스테반
아더 학 리챠드
마리온 미야시로 쥴리
Original Assignee
폴 디. 매튜카이티스
지.디.썰 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴 디. 매튜카이티스, 지.디.썰 앤드 캄파니 filed Critical 폴 디. 매튜카이티스
Publication of KR910011820A publication Critical patent/KR910011820A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/74—Unsaturated compounds containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/19—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups having unsaturation outside the aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/30—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/38—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

내용 없음

Description

LTB4 합성 저해제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (34)

  1. 다음식 :
    의 화합물 또는 약학적으로 허용되는 그의염.
    식중 X는 산소, 황 -CH=CH- 또는 -CH=N-이고; Y는 있을 경우, 수소 또는 할로겐이고; R1은 탄소수가 약 1 내지 20인 알킬, 알케닐 또는 알키닐이고; R2은 -CO2R2, 테트라졸, 메틸술폰아미드 또는 벤젠술포아미드이고, R2는 수소, 탄소수 1 내지 6인 알킬 또는 약학적으로 허용되는 양이온이고; R3은 히드록시 또는 할로겐이다.
  2. 제1항에 있어서, 다음식 :
    의 화합물 또는 약학적으로 허용되는 그의 염.
  3. 제2항에 있어서, X가 -CH=CH-인 것을 특징으로 하는 화합물.
  4. 제3항에 있어서, R1이 탄소수가 1 내지 20인 알킬인 것을 특징으로 하는 화합물.
  5. 제2항에 있어서, X가 0인 것을 특징으로 하는 화합물.
  6. 제5항에 있어서, R1이 탄소수가 1 내지 20인 알킬인 것을 특징으로 하는 화합물.
  7. 제2항에 있어서, X가 S인 것을 특징으로 하는 화합물.
  8. 제7항에 있어서, R1이 탄소수가 1 내지 20인 알킬인 것을 특징으로 하는 화합물.
  9. 제2항에 있어서, 다음식 :
    의 화합물.
  10. 제2항에 있어서, 다음식 :
    의 화합물.
  11. 제2항에 있어서, 다음식 :
    의 화합물.
  12. 제2항에 있어서, 다음식 :
    의 화합물.
  13. 제2항에 있어서, 다음식 :
    의 화합물.
  14. 제2항에 있어서, 다음식 :
    의 화합물.
  15. 제2항에 있어서, 다음식 :
    의 화합물.
  16. 제2항에 있어서, 다음식 :
    의 화합물.
  17. 제2항에 있어서, 다음식 :
    의 화합물.
  18. 제2항에 있어서, 다음식 :
    로부터 선택된 화합물.
  19. 제2항에 있어서, 다음식 :
    의 화합물.
  20. 제2항에 있어서, 다음식 :
    의 화합물.
  21. 제2항에 있어서, 다음식 :
    의 화합물.
  22. 제2항에 있어서, 다음식 :
    의 화합물.
  23. 제2항에 있어서, 다음식 :
    의 화합물.
  24. 제2항에 있어서, 다음식 :
    의 화합물.
  25. 제2항에 있어서, 다음식 :
    의 화합물.
  26. 제2항에 있어서, 다음식 :
    의 화합물.
  27. 제2항에 있어서, 다음식 :
    의 화합물.
  28. 제2항에 있어서, 다음식 :
    의 화합물.
  29. 제2항에 있어서, 다음식 :
    의 화합물.
  30. 제2항에 있어서, 다음식 :
    의 화합물.
  31. 제약학적으로 허용되는 담체중의 치료 또는 예방에 효과적인 양의 제1항에 따른 화합물로 이루어지는 것을 특징으로 하는 제약학적 조성물.
  32. 제31항에 있어서, 상기한 조성물이 경구 투여형태인 것을 특징으로 하는 제약학적 조성물.
  33. 제약학적으로 허용되는 담체중의 치료에 효과적인 양의 제31항에 따른 화합물을 도러한 치료를 필요로하는 환자에게 투여하는 것으로 이루어지는 것을 특징으로 하는, 포유동물에서의 염증상태의 치료방법.
  34. 제약학적으로 허용되는 담체중의 예방에 효과적인 양의 제1항에 따른 화합물을 그러한 병에 걸리기 쉬운 환자에게 투여하는 것으로 이루어지는 것을 특징으로 하는 포유동물에서의 염증성 발병의 예방방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900020892A 1989-12-08 1990-12-18 Ltb4 합성 저해제 KR910011820A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US452138 1989-12-18
US07/452,138 US5086067A (en) 1989-12-18 1989-12-18 Ltb4 synthesis inhibitors

Publications (1)

Publication Number Publication Date
KR910011820A true KR910011820A (ko) 1991-08-07

Family

ID=23795198

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900020892A KR910011820A (ko) 1989-12-08 1990-12-18 Ltb4 합성 저해제

Country Status (10)

Country Link
US (1) US5086067A (ko)
EP (1) EP0435134B1 (ko)
JP (1) JPH04210939A (ko)
KR (1) KR910011820A (ko)
AT (1) ATE124029T1 (ko)
CA (1) CA2032393A1 (ko)
DE (1) DE69020323D1 (ko)
IE (1) IE904553A1 (ko)
PT (1) PT96218A (ko)
TW (1) TW217404B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112864A (en) * 1991-05-30 1992-05-12 G. D. Searle & Co. PLA2 inhibitors as antiinflammatories
US20060058225A1 (en) * 2002-05-31 2006-03-16 Mcgill University Used of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease
US7579002B2 (en) * 2003-12-05 2009-08-25 Wisconsin Alumni Research Foundation Method for improving body weight uniformity and increasing carcass yield in animals
WO2005081954A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3255241A (en) * 1961-01-19 1966-06-07 Merck & Co Inc (2-alkylidene acyl)phenoxy-and (2-alkylidene acyl)phenylmercaptocarboxylic acids
US3919250A (en) * 1972-04-27 1975-11-11 Hoffmann La Roche Catalytic rearrangement of acetylenic carbinois to a {60 ,{62 -unsaturated carbonyl compounds
GB1409323A (en) * 1972-11-02 1975-10-08 Roche Products Ltd Process for the manufacture of oxo compounds
GB1457025A (en) * 1974-04-26 1976-12-01 Roche Products Ltd Process for the manufacture of oxo compounds
US4015010A (en) * 1975-03-03 1977-03-29 Sandoz, Inc. Alkanoyl substituted benzoic acids and esters
US4499295A (en) * 1983-05-09 1985-02-12 G. D. Searle & Co. Protease inhibitors
US4469885A (en) * 1983-05-09 1984-09-04 G. D. Searle & Co. Halogenated protease inhibitors
DE3462487D1 (en) * 1983-11-16 1987-04-09 Beecham Group Plc Arachidonic acid analogues, processes for their preparation and their use in medicine

Also Published As

Publication number Publication date
ATE124029T1 (de) 1995-07-15
US5086067A (en) 1992-02-04
EP0435134A3 (en) 1992-05-13
TW217404B (ko) 1993-12-11
PT96218A (pt) 1991-09-30
EP0435134A2 (en) 1991-07-03
EP0435134B1 (en) 1995-06-21
JPH04210939A (ja) 1992-08-03
DE69020323D1 (de) 1995-07-27
IE904553A1 (en) 1991-06-19
CA2032393A1 (en) 1991-06-19

Similar Documents

Publication Publication Date Title
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR900011772A (ko) 3-(1,2,5,6-테트라하이드로피리딜)피롤로피리딘
KR950031068A (ko) 골다공증의 복합 치료
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
KR870003974A (ko) 비시클로 치환된 페닐아세토니트릴 유도체
KR890016966A (ko) 신규 항바이러스제
KR950010892A (ko) 자궁 섬유증 억제 방법
RU94044454A (ru) Ингибитор аутоимунных заболеваний
PT911331E (pt) Compostos de dibenzoxazepina substituidos composicoes farmaceuticas e metodos de utilizacao
KR950010891A (ko) 내성 종양을 치료하는 방법
KR890003691A (ko) 피페리딘 유도체 및 그를 함유하는 부정맥을 위한 치료예방제
KR970025615A (ko) 암 전이 억제제
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950703527A (ko) 프로스타글란딘 유도체
RU94044489A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования миелопероксидазной активности
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
RO117760B1 (ro) Metodă pentru tratamentul unei afecţiuni de neurotransmisie serotoninergică defectivă
DK0506772T3 (da) Farmaceutisk præparat indeholdende et phosphosukker
RU94045156A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования преждевременного полового созревания
KR890014107A (ko) 백금 화학 요법약제
KR950702554A (ko) 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents)
KR940021064A (ko) 프레그네인 유도체의 사용 방법
KR910011820A (ko) Ltb4 합성 저해제
EP0366561A3 (fr) Nouveaux dérivés 1-azabicycloalkanes, leur procédé de préparation et leur application comme médicaments
HUP9802736A2 (hu) 1,4-Dihidropiridin-származékok alkalmazása artériafal ateroszklerózisos degradálódásának megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid